I-964

TREATMENT OF THE CARDIOMYOPATHY OF WILD-TYPE OR HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS IN ADULTS TO REDUCE CARDIOVASCULAR MORTALITY, CARDIOVASCULAR HOSPITALIZATIONS AND URGENT HEART FAILURE VISITS